2020
Association between halo nevi and melanoma in adults: A multicenter retrospective case series
Haynes D, Strunck JL, Said J, Tam I, Varedi A, Topham CA, Olamiju B, Wei BM, Erickson MK, Wang LL, Tan A, Stoner R, Hartman RI, Lilly E, Grossman D, Curtis JA, Westerdahl JS, Leventhal JS, Choi JN, Chu EY, Ming ME, Stein JA, Liebman TN, Berry E, Greiling TM. Association between halo nevi and melanoma in adults: A multicenter retrospective case series. Journal Of The American Academy Of Dermatology 2020, 84: 1164-1166. PMID: 32822787, DOI: 10.1016/j.jaad.2020.08.056.Peer-Reviewed Original ResearchManagement of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies
Olamiju B, Bhullar S, Coleman EL, Leventhal JS. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies. Journal Of The American Academy Of Dermatology 2020, 84: 806-808. PMID: 32526318, DOI: 10.1016/j.jaad.2020.06.010.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, TopicalAdrenergic beta-AntagonistsAgedAngiolymphoid Hyperplasia with EosinophiliaAnti-Bacterial AgentsAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyCryotherapyErbB ReceptorsFemaleHead and Neck NeoplasmsHumansLung NeoplasmsMaleMiddle AgedParonychiaProtein Kinase InhibitorsRetrospective StudiesSeverity of Illness IndexSilver NitrateTimololTreatment OutcomeEpidemiology, treatment, survival, and prognostic factors of cutaneous mucoepidermoid carcinoma: A distinct entity with an indolent clinical course
Mirza FN, Yumeen S, Zogg CK, Mirza HN, Leventhal JS. Epidemiology, treatment, survival, and prognostic factors of cutaneous mucoepidermoid carcinoma: A distinct entity with an indolent clinical course. Journal Of The American Academy Of Dermatology 2020, 83: 1827-1830. PMID: 32446830, PMCID: PMC7669598, DOI: 10.1016/j.jaad.2020.05.086.Peer-Reviewed Original Research
2019
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease
Coleman E, Panse G, Cowper S, Prebet T, Gore S, Leventhal J. Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. Journal Of Cutaneous Pathology 2019, 46: 930-934. PMID: 31254406, DOI: 10.1111/cup.13537.Peer-Reviewed Original ResearchConceptsLobular neutrophilic panniculitisNeutrophilic panniculitisDNA methyltransferase inhibitorNeutrophilic eccrine hidradenitisInjection site reactionsAcute myelogenous leukemiaMethyltransferase inhibitorNeutrophilic dermatosisSweet's syndromeMaculopapular eruptionCutaneous toxicityHistopathologic characteristicsSite reactionsNext-generation agentsDifferential diagnosisMyelogenous leukemiaTreatment considerationsMyeloid diseasesPanniculitisTreatmentInhibitorsFirst reportGangrenosumHidradenitisEcchymosisTopical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy
Atzmony L, Lim YH, Hamilton C, Leventhal JS, Wagner A, Paller AS, Choate KA. Topical cholesterol/lovastatin for the treatment of porokeratosis: A pathogenesis-directed therapy. Journal Of The American Academy Of Dermatology 2019, 82: 123-131. PMID: 31449901, PMCID: PMC7039698, DOI: 10.1016/j.jaad.2019.08.043.Peer-Reviewed Original ResearchConceptsPorokeratosis lesionsPorokeratosis palmaris et plantaris disseminataPathogenesis-directed therapyTreatment of porokeratosisWeeks of therapyInitiation of therapyPathway gene mutationsDisseminated superficial actinic porokeratosisPathogenesis-based therapiesCase series designSuperficial actinic porokeratosisAdverse eventsTopical therapyTherapeutic optionsComplete clearanceLinear porokeratosisPatientsActinic porokeratosisTherapyPorokeratosisLesionsGene mutationsModerate improvementLovastatinToxic metabolitesJanus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare
Damsky W, Thakral D, McGeary MK, Leventhal J, Galan A, King B. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare. Journal Of The American Academy Of Dermatology 2019, 82: 612-621. PMID: 31185230, PMCID: PMC7590533, DOI: 10.1016/j.jaad.2019.05.098.Peer-Reviewed Original ResearchConceptsGranuloma annulareCutaneous sarcoidosisPathway activationCutaneous granulomatous disordersRecalcitrant cutaneous sarcoidosisSkin biopsy specimensSignal regulatory protein αJAK-STAT pathway activationTranscription (JAK/STAT) pathway activationRegulatory protein αRecalcitrant sarcoidosisSarcoidosis activityDisease remissionConsecutive patientsGranulomatous disorderProspective evaluationBiopsy specimensHistologic resolutionSkin biopsiesMean improvementSarcoidosisImmunohistochemical analysisJAK inhibitorsJAK inhibitionPatientsMultiple Lip Papules and Nodules in an Adult Man
Smith N, Glusac E, Leventhal J. Multiple Lip Papules and Nodules in an Adult Man. JAMA Dermatology 2019, 155: 485-486. PMID: 30840027, DOI: 10.1001/jamadermatol.2018.5240.Peer-Reviewed Original ResearchRadiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy
Mittal A, Mittal V, Panse G, Choi JN, Kwong BY, Leventhal JS. Radiation-induced morphea: Association with autoimmune comorbidities, severity, and response to therapy. Journal Of The American Academy Of Dermatology 2019, 81: 260-262. PMID: 30797843, DOI: 10.1016/j.jaad.2019.02.039.Peer-Reviewed Original Research
2018
Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management
Coleman E, Ko C, Dai F, Tomayko MM, Kluger H, Leventhal JS. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management. Journal Of The American Academy Of Dermatology 2018, 80: 990-997. PMID: 30399387, PMCID: PMC6420863, DOI: 10.1016/j.jaad.2018.10.062.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDrug EruptionsExanthemaFemaleHumansIpilimumabLichenoid EruptionsMaleMiddle AgedNivolumabRetrospective StudiesSkin NeoplasmsStevens-Johnson SyndromeWithholding TreatmentConceptsInflammatory eruptionsCheckpoint inhibitorsTherapeutic responseImmune checkpoint inhibitor therapySingle tertiary care centerSingle-institution retrospective analysisYale-New Haven HospitalCheckpoint inhibitor therapyTertiary care centerMinority of patientsInpatient dermatology serviceDegree of severityMost rashesInhibitor therapyRetrospective studyTopical treatmentEarly recognitionMedical recordsCare centerInflammatory reactionRetrospective analysisDermatology servicesImmunotherapyMean latencyGrade 2Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, Goldberg SB, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tomayko MM, Leventhal JS. Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. Journal Of The American Academy Of Dermatology 2018, 79: 1081-1088. PMID: 30025829, DOI: 10.1016/j.jaad.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalB7-H1 AntigenDrug EruptionsFemaleHumansLichenoid EruptionsMaleMiddle AgedNeoplasm ProteinsNeoplasmsNivolumabPemphigoid, BullousProgrammed Cell Death 1 ReceptorRetrospective StudiesSkin Diseases, VesiculobullousTertiary Care CentersTreatment OutcomeConceptsPD-L1 therapyAnti-PD-1/PD-L1 therapyBullous disordersBullous eruptionPD-1/PD-L1 therapyCell death ligand-1 therapyAnti-programmed cell death 1Cancer therapyDeath ligand 1 therapySingle tertiary care centerLinear IgA bullous dermatosisYale-New Haven HospitalDistinct therapeutic challengesInterruption of immunotherapyPositive tumor responseSteroid-sparing agentTertiary care centerIgA bullous dermatosisCell death 1New Haven HospitalStable diseaseSystemic corticosteroidsSystemic steroidsMaintenance therapyL1 therapyNecrotic cheek ulcer in a liver transplant patient
Coleman E, Levy L, Panse G, Leventhal JS. Necrotic cheek ulcer in a liver transplant patient. International Journal Of Dermatology 2018, 58: 285-287. PMID: 29926899, PMCID: PMC6309531, DOI: 10.1111/ijd.14101.Peer-Reviewed Original ResearchErythema Nodosum–like Eruption in the Setting of Sorafenib Therapy
Coleman EL, Cowper SE, Stein SM, Leventhal JS. Erythema Nodosum–like Eruption in the Setting of Sorafenib Therapy. JAMA Dermatology 2018, 154: 369-370. PMID: 29453869, DOI: 10.1001/jamadermatol.2017.5733.Peer-Reviewed Case Reports and Technical Notes
2017
Cyanosis of the foot.
Shi VJ, Leventhal JS, Mensah KA, Galan A, Choate KA. Cyanosis of the foot. Cutis 2017, 100: 206;209;210. PMID: 29136053.Peer-Reviewed Original ResearchGeneralized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab
Li AW, Ko CJ, Leventhal JS. Generalized lichen nitidus-like eruption in the setting of mogamulizumab and tremelimumab. European Journal Of Dermatology 2017, 27: 325-326. PMID: 28414193, DOI: 10.1684/ejd.2017.2989.Peer-Reviewed Original Research
2016
Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy
Shi VJ, Rodic N, Gettinger S, Leventhal JS, Neckman JP, Girardi M, Bosenberg M, Choi JN. Clinical and Histologic Features of Lichenoid Mucocutaneous Eruptions Due to Anti–Programmed Cell Death 1 and Anti–Programmed Cell Death Ligand 1 Immunotherapy. JAMA Dermatology 2016, 152: 1128-1136. PMID: 27411054, PMCID: PMC6108080, DOI: 10.1001/jamadermatol.2016.2226.Peer-Reviewed Original ResearchConceptsAnti-PD-1/PD-L1 therapyCutaneous adverse effectsPD-L1 therapyCell death 1Concurrent medicationsDeath-1Adverse effectsClinical morphologyAnti-PD-1/PD-L1 treatmentAnti-programmed cell death ligand-1 (PD-L1) immunotherapiesAnti-programmed cell death 1Non-small cell lung cancerDeath ligand 1 (PD-L1) immunotherapyPD-L1 antibody therapyCell death ligand 1Yale-New Haven HospitalMucocutaneous adverse effectsPD-L1 treatmentTreatment of rashTertiary care hospitalDeath ligand 1Lichenoid drug eruptionCell lung cancerSkin biopsy specimensRecent US FoodA 54‐year‐old woman with arthritis and discoloration of the hands, ears, and sclerae
Yin ES, Knispel JD, McNiff JM, Leventhal JS. A 54‐year‐old woman with arthritis and discoloration of the hands, ears, and sclerae. International Journal Of Dermatology 2016, 56: 715-717. PMID: 27651033, DOI: 10.1111/ijd.13415.Peer-Reviewed Original Research
2013
Crystal deodorant‐induced axillary granulomatous dermatitis
Leventhal JS, Farhadian JA, Miller KE, Tlougan BE, Patel RR, Sanchez MR. Crystal deodorant‐induced axillary granulomatous dermatitis. International Journal Of Dermatology 2013, 53: e59-e60. PMID: 23621443, DOI: 10.1111/j.1365-4632.2012.05686.x.Peer-Reviewed Original Research